Steven N. Perrin
President, Chief Scientific Officer & Non Independent DirectorDr. Steven N. Perrin, Ph.D., also known as Steve, is President, Treasurer & Director of Anelixis Therapeutics, LLC. Dr. Perrin is Non Independent Director, President and Chief Scientific Officer at Eledon Pharmaceuticals, Inc. (formerly known as Novus Therapeutics, Inc.) since September 14, 2020. He serves as the Chief Executive Officer at ALS Therapy Development Institute since June 2010 and served as its Chief Scientific Officer since January 2007 until August 2018. Dr. Perrin served as Chief Executive Officer of Anelixis Therapeutics since January 2013 and has been Executive Chairman of the ALS Therapy Development Institute since June 2010. Dr. Perrin moved into the pharmaceutical industry in 1997 holding positions at the Hoechst-Ariad Genomics Center, Aventis Pharmaceuticals and served as Associate Director of Molecular Profiling at Biogen Idec from January 2005 to December 2006. He joined ALS TDI in 2007 as part of historical collaboration between the Muscular Dystrophy Association, Augie's Quest and ALS TDI to develop effective therapeutics for ALS patients. Since joining ALS TDI, he has spearheaded the development of computational biology capabilities and information management systems to more clearly understand the molecular mechanisms associated with disease onset and progression in neurodegenerative diseases. He has expanded ALS TDI's drug screening program to include expertise in the generation and assessment of gene therapy vectors and protein biologics in preclinical models of neurodegeneration. He has developed a business plan to facilitate pharmaceutical partnerships for rapid clinical development and commercialization of promising targets for ALS patients. He is a frequent participant in international conferences in computational biology, genomics, drug development and neurodegeneration. Dr. Perrin received his Bachelor of Science in Biology from Boston College in 1987 and earned his Ph.D. in Biochemistry at Boston University School of Medicine in 1994.
公司职务
- 公司名称Eledon Pharmaceuticals, Inc.股票代码ELDN职务President, Chief Scientific Officer & Non Independent Director共事同僚
- DCDavid-Alexandre C. GrosCEO & Non Independent Director
- KAKeith A. KatkinIndependent Chairman of the Board
- PSPaul Sean LittleChief Financial Officer
- JHJohn HerbergerVice President of Technical Operations
- BEBryan E. SmithGeneral Counsel, Corporate Secretary & Chief Compliance Officer
- JSJohn S. McBrideIndependent Director
- JAJames A. RobinsonIndependent Director
